The Definition, Classification, and History of Urticaria.

The term "urticaria" was first introduced by William Cullen in the eighteenth century. Urticaria is a common mast cell-mediated cutaneous disease presenting with pruritic wheals, angioedema, or both. It is classified as acute (≤6 weeks) or chronic (>6 weeks) and as spontaneous (no definite triggers) or inducible (definite and subtype-specific triggers). The international urticaria guideline on the definition, classification, diagnosis, and management of urticaria is revised every 4 years. The global network of Urticaria Centers of Reference and Excellence, the biggest and most active consortium of urticaria specialists, offers physicians and patients several research, educational, and digital care initiatives.
Competing Interests: Disclosure M. Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Almirall, Spaim, Alvotech, Amgen, United States, Aquestive, Aralez, AstraZeneca, United Kingdom, Bayer, Germany, Celldex, United States, Celltrion, South Korea, Evommune, GSK, Ipsen, France, Janssen, United States, Kyowa Kirin, LEO Pharma, Denmark, Lilly, Menarini, Mitsubishi Tanabe Pharma, Japan, Moxie, Noucor, Novartis, Switzerland, Orion, Pfizer, United States, Resoncance Medicine, Sanofi/Regeneron, Septerna, Third Harmonic Bio, ValenzaBio, Yuhan Corporation, South Korea, and Zurabio. M.P. Pereira is an investigator for Allakos, Celldex Therapeutics, Incyte, Sanofi and Trevi Therapeutics and is/was an advisor and/or speaker and/or has received research funding from AbbVie, United States, Almirall, Beiersdorf, Germany, Eli Lilly, GA(2)LEN, Galderma, Switzerland, Menlo Therapeutics, Novartis, P.G. Unna Academy, Sanofi, United States and Trevi Therapeutics. P. Kolkhir is or recently was a speaker and/or advisor for and/or has received research funding from Novartis, Roche, Switzerland, and ValenzaBio outside of submitted work.
(Copyright © 2024 Elsevier Inc. All rights reserved.)